ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and effectiveness of Iressa when used with a short course of high dose radiation therapy in patients with lung cancer.
Checked against the public recordLast updated May 4, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Interventions being studied
- Drug: ZD1839 (Iressa); Radiation: Thoracic Radiotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically confirmed non small cell lung cancer * Stage IV needing radiation therapy to control symptoms * Patients with brain metastases * Unresectable or medically inoperable Exclusion Criteria: * Small cell lung cancer * Previous thoracic radiation therapy * Oxygen-dependent patients * Forced expiratory volume in 1 second (FEV1) less than 1.5 * Patients with active interstitial lung disease * Patients with underlying lung disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 4, 2025. Always confirm current availability with the study team.